Zymeworks Inc

ZYME

$33.03

+2.2% (1 year change)

Market Cap

$1.49 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$24.82 - $59.03

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-6.69x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $1.49 Billion
Enterprise Value $1.13 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +2.2%
52-Week High $59.03
52-Week Low $24.82
Beta 1.13
Outstanding Shares 46.4 Million
Avg 30 Day Volume 268 Thousand

Valuation

P/E Ratio -6.69
PEG -15.49
Earnings per Share -$4.35
Price to Sales Ratio Infinity
Price to Book Ratio 5.51
Revenue to Enterprise Value 36.08
EBIT to Enterprise Value -5.75
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $31.3 Million
Gross Profit $31.3 Million
EBIT -$197 Million
Net Income -$194 Million
Profit Margin -619.31%
Quarterly Earnings Growth (YoY) +43.2%
Return on Equity -60.35%
Return on Assets -41.11%
Return on Invested Capital -50.53%

News

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

VANCOUVER, British Columbia--(BUSINESS WIRE)--This press release announces the availability of an abstract that Zymeworks is presenting at the upcoming ESMO Congress

Business Wire Business Wire, 4 days ago
Zymeworks EPS misses by $0.02, misses on revenue

Zymeworks EPS misses by $0.02, misses on revenue

No summary available.

Seeking Alpha Seeking Alpha, about 1 month ago
Zymeworks gets milestone payment under JNJ-78278343 Janssen Biotech licensing deal

Zymeworks gets milestone payment under JNJ-78278343 Janssen Biotech licensing deal

No summary available.

Seeking Alpha Seeking Alpha, about 1 month ago